Skin Involvement in Systemic Vasculitis: Evaluation and Treatment
Skin involvement in systemic vasculitis should be evaluated through clinical assessment of lesion type and severity, supported by skin biopsy showing leukocytoclastic vasculitis, and treated according to whether disease is isolated cutaneous or part of severe systemic vasculitis—with isolated skin lesions managed by topical corticosteroids or colchicine, while systemic disease requires rituximab or cyclophosphamide plus glucocorticoids.
Clinical Evaluation
Key Clinical Features to Assess
Determine disease severity by identifying life-threatening manifestations:
- Ulcerative or necrotic skin lesions suggest severe disease requiring systemic immunosuppression 1, 2
- Palpable purpura, papules, or nodules indicate small-vessel involvement 3
- Constitutional symptoms (fever, weight loss, malaise) signal systemic disease 2, 4
- Extracutaneous manifestations including:
Diagnostic Workup
Essential investigations include:
- Skin biopsy from active lesion showing leukocytoclastic vasculitis with fibrinoid necrosis 6, 7
- ANCA testing (MPO-ANCA or PR3-ANCA) if systemic AAV suspected 5
- Urinalysis with microscopy for dysmorphic RBCs and red cell casts 5
- Complete blood count, CRP/ESR, renal function 5
- Direct immunofluorescence to exclude IgA vasculitis or other immune complex disease 3
Treatment Algorithm
For Isolated Cutaneous Vasculitis (No Systemic Involvement)
First-line approach:
- Topical corticosteroids for localized lesions 8
- Colchicine preferred when erythema nodosum is the dominant lesion 8
- Supportive measures including leg elevation and wound care
For resistant isolated cutaneous disease:
For Severe Systemic Vasculitis with Skin Involvement
Remission induction (choose one regimen):
Preferred: Rituximab-based regimen 1, 6, 10
- Rituximab 375 mg/m² IV weekly × 4 doses OR 1000 mg IV on days 1 and 15
- PLUS high-dose glucocorticoids: methylprednisolone 1 mg/kg/day (max 80 mg) or IV pulse methylprednisolone 500-1000 mg/day × 3-5 days 1
- Taper glucocorticoids to 5-7.5 mg/day by 3-6 months 5
Alternative: Cyclophosphamide-based regimen 1, 6
- Cyclophosphamide 15 mg/kg IV every 2 weeks × 3 doses, then every 3 weeks × 3+ doses
- PLUS glucocorticoids as above
- Limit cyclophosphamide to 3-6 months maximum due to toxicity 11
Maintenance therapy (after achieving remission):
- Rituximab 500 mg IV every 6 months (preferred) 5, 6, 10
- OR azathioprine 2 mg/kg/day 9, 6
- OR methotrexate up to 25 mg/week 1
- Continue maintenance for minimum 2 years 5
- Maintain glucocorticoids at ≤7.5 mg/day 12
For Relapsing Disease
Re-induce with rituximab preferentially 5, using same dosing as initial induction
For Refractory Disease
- Increase glucocorticoids (IV or oral) 5
- Switch from cyclophosphamide to rituximab or vice versa 5
- Consider plasma exchange in severe cases 5
Critical Pitfalls to Avoid
Do not delay treatment while awaiting biopsy results if clinical presentation strongly suggests systemic vasculitis with positive ANCA 5, 6
Avoid ciclosporine A in patients with neurological involvement due to neurotoxicity risk 8
Monitor for cyclophosphamide complications:
- Perform periodic urinalysis for hematuria (bladder cancer risk) throughout follow-up 6
- Check complete blood count regularly for myelosuppression
Do not continue cyclophosphamide beyond 3-6 months due to cumulative toxicity including malignancy risk 8, 11
Special Considerations
For Behçet disease with mucocutaneous involvement:
- Topical measures first-line for oral/genital ulcers 8
- Colchicine for erythema nodosum 8
- Azathioprine, IFNα, or TNF antagonists for resistant cases 8
Multidisciplinary management is essential given the rarity and complexity of systemic vasculitis—patients should be managed by or with ready access to specialized vasculitis centers 6, 10